img

Global and India VMAT2 Inhibitors Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and India VMAT2 Inhibitors Market Report & Forecast 2024-2034

Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington’s disease.
Market Analysis and InsightsGlobal and India VMAT2 Inhibitors Market
This report focuses on global and India VMAT2 Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
The global VMAT2 Inhibitors revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the VMAT2 Inhibitors revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of VMAT2 Inhibitors include Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Hetero, Bausch Health Companies Inc, Dr. Reddy's Laboratories Ltd, Piramal Pharma Solution and Lupin, etc. The global five biggest players hold a share of % in 2024.
Global VMAT2 Inhibitors Scope and Market Size
VMAT2 Inhibitors market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global VMAT2 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the VMAT2 Inhibitors market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.



By Company


Neurocrine Biosciences, Inc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Hikma Pharmaceuticals plc
Hetero
Bausch Health Companies Inc
Dr. Reddy's Laboratories Ltd
Piramal Pharma Solution
Lupin
Luye Pharma Group
Segment by Type
Tetrabenazine
Valbenazine
Other

Segment by Application


Huntington’s Disease
Tardive Dyskinesia
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces VMAT2 Inhibitors definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of VMAT2 Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of VMAT2 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, VMAT2 Inhibitors sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 VMAT2 Inhibitors Product Introduction
1.2 Global VMAT2 Inhibitors Outlook 2018 VS 2024 VS 2034
1.2.1 Global VMAT2 Inhibitors Sales in US$ Million for the Year 2018-2034
1.2.2 Global VMAT2 Inhibitors Sales in Volume for the Year 2018-2034
1.3 India VMAT2 Inhibitors Outlook 2018 VS 2024 VS 2034
1.3.1 India VMAT2 Inhibitors Sales in US$ Million for the Year 2018-2034
1.3.2 India VMAT2 Inhibitors Sales in Volume for the Year 2018-2034
1.4 VMAT2 Inhibitors Market Size, India VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of India VMAT2 Inhibitors in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of VMAT2 Inhibitors Market Size, India VS Global, 2018 VS 2024 VS 2034
1.5 VMAT2 Inhibitors Market Dynamics
1.5.1 VMAT2 Inhibitors Industry Trends
1.5.2 VMAT2 Inhibitors Market Drivers
1.5.3 VMAT2 Inhibitors Market Challenges
1.5.4 VMAT2 Inhibitors Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 VMAT2 Inhibitors by Type
2.1 VMAT2 Inhibitors Market Segment by Type
2.1.1 Tetrabenazine
2.1.2 Valbenazine
2.1.3 Other
2.2 Global VMAT2 Inhibitors Market Size by Type
2.2.1 Global VMAT2 Inhibitors Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global VMAT2 Inhibitors Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 India VMAT2 Inhibitors Market Size by Type
2.3.1 India VMAT2 Inhibitors Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 India VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 India VMAT2 Inhibitors Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 VMAT2 Inhibitors by Application
3.1 VMAT2 Inhibitors Market Segment by Application
3.1.1 Huntington’s Disease
3.1.2 Tardive Dyskinesia
3.1.3 Other
3.2 Global VMAT2 Inhibitors Market Size by Application
3.2.1 Global VMAT2 Inhibitors Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global VMAT2 Inhibitors Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 India VMAT2 Inhibitors Market Size by Application
3.3.1 India VMAT2 Inhibitors Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 India VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 India VMAT2 Inhibitors Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global VMAT2 Inhibitors Competitor Landscape by Company
4.1 Global VMAT2 Inhibitors Market Size by Company
4.1.1 Global Key Manufacturers of VMAT2 Inhibitors, Ranked by Revenue (2024)
4.1.2 Global VMAT2 Inhibitors Revenue by Manufacturer (2018-2023)
4.1.3 Global VMAT2 Inhibitors Sales by Manufacturer (2018-2023)
4.1.4 Global VMAT2 Inhibitors Price by Manufacturer (2018-2023)
4.2 Global VMAT2 Inhibitors Concentration Ratio (CR)
4.2.1 VMAT2 Inhibitors Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of VMAT2 Inhibitors in 2024
4.2.3 Global VMAT2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of VMAT2 Inhibitors, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of VMAT2 Inhibitors, Product Offered and Application
4.5 Global Key Manufacturers of VMAT2 Inhibitors, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India VMAT2 Inhibitors Market Size by Company
4.7.1 Key Players of VMAT2 Inhibitors in India, Ranked by Revenue (2024)
4.7.2 India VMAT2 Inhibitors Revenue by Players (2018-2023)
4.7.3 India VMAT2 Inhibitors Sales by Players (2018-2023)
5 Global VMAT2 Inhibitors Market Size by Region
5.1 Global VMAT2 Inhibitors Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global VMAT2 Inhibitors Market Size in Volume by Region (2018-2034)
5.2.1 Global VMAT2 Inhibitors Sales in Volume by Region: 2018-2023
5.2.2 Global VMAT2 Inhibitors Sales in Volume Forecast by Region (2024-2034)
5.3 Global VMAT2 Inhibitors Market Size in Value by Region (2018-2034)
5.3.1 Global VMAT2 Inhibitors Sales in Value by Region: 2018-2023
5.3.2 Global VMAT2 Inhibitors Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas VMAT2 Inhibitors Market Size YoY Growth 2018-2034
6.2 Americas VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas VMAT2 Inhibitors Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas VMAT2 Inhibitors Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas VMAT2 Inhibitors Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA VMAT2 Inhibitors Market Size YoY Growth 2018-2034
7.2 EMEA VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA VMAT2 Inhibitors Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA VMAT2 Inhibitors Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA VMAT2 Inhibitors Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China VMAT2 Inhibitors Market Size YoY Growth 2018-2034
8.2 China VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC VMAT2 Inhibitors Market Size YoY Growth 2018-2034
9.2 APAC VMAT2 Inhibitors Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC VMAT2 Inhibitors Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC VMAT2 Inhibitors Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC VMAT2 Inhibitors Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC VMAT2 Inhibitors Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Neurocrine Biosciences, Inc
10.1.1 Neurocrine Biosciences, Inc Company Information
10.1.2 Neurocrine Biosciences, Inc Description and Business Overview
10.1.3 Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Neurocrine Biosciences, Inc VMAT2 Inhibitors Products Offered
10.1.5 Neurocrine Biosciences, Inc Recent Development
10.2 Teva Pharmaceutical Industries Ltd
10.2.1 Teva Pharmaceutical Industries Ltd Company Information
10.2.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
10.2.3 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Products Offered
10.2.5 Teva Pharmaceutical Industries Ltd Recent Development
10.3 Sun Pharmaceutical Industries Ltd
10.3.1 Sun Pharmaceutical Industries Ltd Company Information
10.3.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
10.3.3 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Products Offered
10.3.5 Sun Pharmaceutical Industries Ltd Recent Development
10.4 Hikma Pharmaceuticals plc
10.4.1 Hikma Pharmaceuticals plc Company Information
10.4.2 Hikma Pharmaceuticals plc Description and Business Overview
10.4.3 Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Hikma Pharmaceuticals plc VMAT2 Inhibitors Products Offered
10.4.5 Hikma Pharmaceuticals plc Recent Development
10.5 Hetero
10.5.1 Hetero Company Information
10.5.2 Hetero Description and Business Overview
10.5.3 Hetero VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Hetero VMAT2 Inhibitors Products Offered
10.5.5 Hetero Recent Development
10.6 Bausch Health Companies Inc
10.6.1 Bausch Health Companies Inc Company Information
10.6.2 Bausch Health Companies Inc Description and Business Overview
10.6.3 Bausch Health Companies Inc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bausch Health Companies Inc VMAT2 Inhibitors Products Offered
10.6.5 Bausch Health Companies Inc Recent Development
10.7 Dr. Reddy's Laboratories Ltd
10.7.1 Dr. Reddy's Laboratories Ltd Company Information
10.7.2 Dr. Reddy's Laboratories Ltd Description and Business Overview
10.7.3 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Products Offered
10.7.5 Dr. Reddy's Laboratories Ltd Recent Development
10.8 Piramal Pharma Solution
10.8.1 Piramal Pharma Solution Company Information
10.8.2 Piramal Pharma Solution Description and Business Overview
10.8.3 Piramal Pharma Solution VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Piramal Pharma Solution VMAT2 Inhibitors Products Offered
10.8.5 Piramal Pharma Solution Recent Development
10.9 Lupin
10.9.1 Lupin Company Information
10.9.2 Lupin Description and Business Overview
10.9.3 Lupin VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Lupin VMAT2 Inhibitors Products Offered
10.9.5 Lupin Recent Development
10.10 Luye Pharma Group
10.10.1 Luye Pharma Group Company Information
10.10.2 Luye Pharma Group Description and Business Overview
10.10.3 Luye Pharma Group VMAT2 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Luye Pharma Group VMAT2 Inhibitors Products Offered
10.10.5 Luye Pharma Group Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 VMAT2 Inhibitors Industry Chain Analysis
11.2 VMAT2 Inhibitors Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 VMAT2 Inhibitors Production Mode & Process
11.4 VMAT2 Inhibitors Sales and Marketing
11.4.1 VMAT2 Inhibitors Sales Channels
11.4.2 VMAT2 Inhibitors Distributors
11.5 VMAT2 Inhibitors Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. VMAT2 Inhibitors CAGR in Value, India VS Global, 2018 VS 2024 VS 2034
Table 2. VMAT2 Inhibitors Market Trends
Table 3. VMAT2 Inhibitors Market Drivers
Table 4. VMAT2 Inhibitors Market Challenges
Table 5. VMAT2 Inhibitors Market Restraints
Table 6. Global VMAT2 Inhibitors Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. India VMAT2 Inhibitors Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global VMAT2 Inhibitors Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. India VMAT2 Inhibitors Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of VMAT2 Inhibitors, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global VMAT2 Inhibitors Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global VMAT2 Inhibitors Revenue Share by Manufacturer, 2018-2023
Table 13. Global VMAT2 Inhibitors Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global VMAT2 Inhibitors Sales Share by Manufacturer, 2018-2023
Table 15. Global VMAT2 Inhibitors Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global VMAT2 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global VMAT2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VMAT2 Inhibitors as of 2024)
Table 18. Global Key Manufacturers of VMAT2 Inhibitors, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of VMAT2 Inhibitors, Product Offered and Application
Table 20. Global Key Manufacturers of VMAT2 Inhibitors, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of VMAT2 Inhibitors in India, Ranked by Revenue (2024) & (US$ million)
Table 23. India VMAT2 Inhibitors Revenue by Players, (US$ Million), (2018-2023)
Table 24. India VMAT2 Inhibitors Revenue Share by Players, (2018-2023)
Table 25. India VMAT2 Inhibitors Sales by Players, (K Units), (2018-2023)
Table 26. India VMAT2 Inhibitors Sales Share by Players, (2018-2023)
Table 27. Global VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global VMAT2 Inhibitors Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global VMAT2 Inhibitors Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global VMAT2 Inhibitors Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global VMAT2 Inhibitors Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas VMAT2 Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas VMAT2 Inhibitors Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas VMAT2 Inhibitors Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas VMAT2 Inhibitors Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA VMAT2 Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA VMAT2 Inhibitors Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA VMAT2 Inhibitors Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA VMAT2 Inhibitors Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC VMAT2 Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC VMAT2 Inhibitors Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC VMAT2 Inhibitors Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC VMAT2 Inhibitors Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Neurocrine Biosciences, Inc Company Information
Table 48. Neurocrine Biosciences, Inc Description and Business Overview
Table 49. Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Neurocrine Biosciences, Inc VMAT2 Inhibitors Product
Table 51. Neurocrine Biosciences, Inc Recent Development
Table 52. Teva Pharmaceutical Industries Ltd Company Information
Table 53. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 54. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product
Table 56. Teva Pharmaceutical Industries Ltd Recent Development
Table 57. Sun Pharmaceutical Industries Ltd Company Information
Table 58. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 59. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product
Table 61. Sun Pharmaceutical Industries Ltd Recent Development
Table 62. Hikma Pharmaceuticals plc Company Information
Table 63. Hikma Pharmaceuticals plc Description and Business Overview
Table 64. Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Hikma Pharmaceuticals plc VMAT2 Inhibitors Product
Table 66. Hikma Pharmaceuticals plc Recent Development
Table 67. Hetero Company Information
Table 68. Hetero Description and Business Overview
Table 69. Hetero VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Hetero VMAT2 Inhibitors Product
Table 71. Hetero Recent Development
Table 72. Bausch Health Companies Inc Company Information
Table 73. Bausch Health Companies Inc Description and Business Overview
Table 74. Bausch Health Companies Inc VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Bausch Health Companies Inc VMAT2 Inhibitors Product
Table 76. Bausch Health Companies Inc Recent Development
Table 77. Dr. Reddy's Laboratories Ltd Company Information
Table 78. Dr. Reddy's Laboratories Ltd Description and Business Overview
Table 79. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product
Table 81. Dr. Reddy's Laboratories Ltd Recent Development
Table 82. Piramal Pharma Solution Company Information
Table 83. Piramal Pharma Solution Description and Business Overview
Table 84. Piramal Pharma Solution VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Piramal Pharma Solution VMAT2 Inhibitors Product
Table 86. Piramal Pharma Solution Recent Development
Table 87. Lupin Company Information
Table 88. Lupin Description and Business Overview
Table 89. Lupin VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Lupin VMAT2 Inhibitors Product
Table 91. Lupin Recent Development
Table 92. Luye Pharma Group Company Information
Table 93. Luye Pharma Group Description and Business Overview
Table 94. Luye Pharma Group VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Luye Pharma Group VMAT2 Inhibitors Product
Table 96. Luye Pharma Group Recent Development
Table 97. Key Raw Materials Lists
Table 98. Raw Materials Key Suppliers Lists
Table 99. VMAT2 Inhibitors Customers List
Table 100. VMAT2 Inhibitors Distributors List
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. VMAT2 Inhibitors Product Picture
Figure 2. Global VMAT2 Inhibitors Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global VMAT2 Inhibitors Market Size 2018-2034 (US$ Million)
Figure 4. Global VMAT2 Inhibitors Sales 2018-2034 (K Units)
Figure 5. India VMAT2 Inhibitors Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. India VMAT2 Inhibitors Market Size 2018-2034 (US$ Million)
Figure 7. India VMAT2 Inhibitors Sales 2018-2034 (K Units)
Figure 8. India VMAT2 Inhibitors Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. India VMAT2 Inhibitors Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. VMAT2 Inhibitors Report Years Considered
Figure 11. Product Picture of Tetrabenazine
Figure 12. Product Picture of Valbenazine
Figure 13. Product Picture of Other
Figure 14. Global VMAT2 Inhibitors Market Share by Type in 2024 & 2034
Figure 15. Global VMAT2 Inhibitors Sales in Value by Type (2018-2034) & (US$ Million)
Figure 16. Global VMAT2 Inhibitors Sales Market Share in Value by Type (2018-2034)
Figure 17. Global VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 18. Global VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 19. Global VMAT2 Inhibitors Price by Type (2018-2034) & (US$/Unit)
Figure 20. India VMAT2 Inhibitors Market Share by Type in 2024 & 2034
Figure 21. India VMAT2 Inhibitors Sales in Value by Type (2018-2034) & (US$ Million)
Figure 22. India VMAT2 Inhibitors Sales Market Share in Value by Type (2018-2034)
Figure 23. India VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 24. India VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 25. India VMAT2 Inhibitors Price by Type (2018-2034) & (US$/Unit)
Figure 26. Product Picture of Huntington’s Disease
Figure 27. Product Picture of Tardive Dyskinesia
Figure 28. Product Picture of Other
Figure 29. Global VMAT2 Inhibitors Market Share by Application in 2024 & 2034
Figure 30. Global VMAT2 Inhibitors Sales in Value by Application (2018-2034) & (US$ Million)
Figure 31. Global VMAT2 Inhibitors Sales Market Share in Value by Application (2018-2034)
Figure 32. Global VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 33. Global VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 34. Global VMAT2 Inhibitors Price by Application (2018-2034) & (US$/Unit)
Figure 35. India VMAT2 Inhibitors Market Share by Application in 2024 & 2034
Figure 36. India VMAT2 Inhibitors Sales in Value by Application (2018-2034) & (US$ Million)
Figure 37. India VMAT2 Inhibitors Sales Market Share in Value by Application (2018-2034)
Figure 38. India VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 39. India VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 40. India VMAT2 Inhibitors Price by Application (2018-2034) & (US$/Unit)
Figure 41. Americas VMAT2 Inhibitors Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 42. Americas VMAT2 Inhibitors Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 43. Americas VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 44. Americas VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 45. Americas VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 46. Americas VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 47. United States VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 48. Canada VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Mexico VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. EMEA VMAT2 Inhibitors Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 52. EMEA VMAT2 Inhibitors Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 53. EMEA VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 54. EMEA VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 55. EMEA VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 56. EMEA VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 57. Europe VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 58. Middle East VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Africa VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. China VMAT2 Inhibitors Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 61. China VMAT2 Inhibitors Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 62. China VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 63. China VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 64. China VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 65. China VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 66. APAC VMAT2 Inhibitors Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 67. APAC VMAT2 Inhibitors Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 68. APAC VMAT2 Inhibitors Sales by Type (2018-2034) & (K Units)
Figure 69. APAC VMAT2 Inhibitors Sales Market Share in Volume by Type (2018-2034)
Figure 70. APAC VMAT2 Inhibitors Sales by Application (2018-2034) & (K Units)
Figure 71. APAC VMAT2 Inhibitors Sales Market Share in Volume by Application (2018-2034)
Figure 72. Japan VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 73. South Korea VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. China Taiwan VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. Southeast Asia VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. India VMAT2 Inhibitors Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. VMAT2 Inhibitors Value Chain
Figure 78. VMAT2 Inhibitors Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries